Striking Dichotomy in Outcome of MYCN-amplified Neuroblastoma in the Contemporary Era

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2014 Apr 3

PMID 24691684

Citations 21

Authors

Brian H Kushner

Shakeel Modak

Kim Kramer

Michael P LaQuaglia

Karima Yataghene

Ellen M Basu

Stephen S Roberts

Nai-Kong V Cheung

Affiliations

Soon will be listed here.

Abstract

Background: The authors exploited a large database to investigate the outcomes of patients with high-risk neuroblastoma in the contemporary era.

Methods: All patients with high-risk neuroblastoma aged <12 years who were treated during induction at the authors' institution from 2000 through 2011 were studied, including 118 patients with MYCN-amplified [MYCN(+)] disease and 127 patients aged >18 months with MYCN-nonamplified [MYCN(-)] stage 4 disease.

Results: A complete response/very good partial response (CR/VGPR) to induction was correlated with significantly superior event-free survival (EFS) (P < .001) and overall survival (OS) (P < .001) compared with a partial response or less. Patients with MYCN(+) and MYCN(-) disease had similar rates of CR/VGPR to induction (P = .366), and those with MYCN(+) and MYCN(-) disease who attained a CR/VGPR had similar EFS (P = .346) and OS (P = .542). In contrast, only MYCN(+) patients had progressive disease as a response to induction (P < .001), and early death from progressive disease (<366 days after diagnosis) was significantly more common (P < .001) among those with MYCN(+) disease. Overall, among patients who had a partial response or less, MYCN(+) patients had significantly inferior EFS (P < .001) and OS (P < .001) compared with MYCN(-) patients, which accounted for the significantly worse EFS (P = .008) and OS (P = .002) for the entire MYCN(+) cohort versus the MYCN(-) cohort.

Conclusions: Patients with MYCN(-), high-risk neuroblastoma display a broad, continuous spectrum with regard to response and outcome, whereas MYCN(+) patients either have an excellent response to induction associated with good long-term outcome or develop early progressive disease with a poor outcome. This extreme dichotomy in the clinical course of MYCN(+) patients points to underlying biologic differences with MYCN(+) neuroblastoma, the elucidation of which may have far-reaching implications, including improved risk classification at diagnosis and the identification of targets for treatment.

Citing Articles

Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.

Gorostegui M, Munoz J, Perez-Jaume S, Simao-Rafael M, Larrosa C, Garraus M Cancers (Basel). 2024; 16(9).

PMID: 38730688 PMC: 11083939. DOI: 10.3390/cancers16091735.

Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.

Munoz J, Larrosa C, Chamorro S, Perez-Jaume S, Simao M, Sanchez-Sierra N Cancers (Basel). 2023; 15(19).

PMID: 37835531 PMC: 10571514. DOI: 10.3390/cancers15194837.

Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.

Mora J, Castaneda A, Gorostegui M, Varo A, Perez-Jaume S, Simao M Cancers (Basel). 2023; 15(9).

PMID: 37174002 PMC: 10177429. DOI: 10.3390/cancers15092535.

Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma.

Lucas Jr J, Wakefield D, Doubrovin M, Li Y, Santiago T, Federico S Clin Transl Radiat Oncol. 2022; 34:42-50.

PMID: 35345864 PMC: 8956847. DOI: 10.1016/j.ctro.2022.02.009.

MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.

Yue Z, Xing T, Zhao W, Zhao Q, Wang X, Su Y Cancer Med. 2022; 11(8):1837-1849.

PMID: 35137546 PMC: 9041068. DOI: 10.1002/cam4.4583.

References

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D . Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol. 2004; 26(4):227-32. DOI: 10.1097/00043426-200404000-00003. View

Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M . Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009; 45(16):2835-42. DOI: 10.1016/j.ejca.2009.06.010. View

Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K . Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol. 2002; 24(8):613-21. DOI: 10.1097/00043426-200211000-00004. View

Cheung N, Cheung I, Kushner B, Ostrovnaya I, Chamberlain E, Kramer K . Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012; 30(26):3264-70. PMC: 3434986. DOI: 10.1200/JCO.2011.41.3807. View

Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling F . Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett. 2003; 197(1-2):11-7. DOI: 10.1016/s0304-3835(03)00076-4. View

Taggart D, London W, Schmidt M, Dubois S, Monclair T, Nakagawara A . Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011; 29(33):4358-64. PMC: 3221520. DOI: 10.1200/JCO.2011.35.9570. View

Kushner B, Kramer K, Modak S, Cheung N . Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol. 2006; 24(33):5271-6. DOI: 10.1200/JCO.2006.06.7272. View

George R, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger R . High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006; 24(18):2891-6. DOI: 10.1200/JCO.2006.05.6986. View

10.

Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola M, Viscardi E . A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003; 98(11):2488-94. DOI: 10.1002/cncr.11797. View

11.

Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V . Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2010; 47(4):561-71. DOI: 10.1016/j.ejca.2010.10.022. View

12.

Park J, Scott J, Stewart C, London W, Naranjo A, Santana V . Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011; 29(33):4351-7. PMC: 3221519. DOI: 10.1200/JCO.2010.34.3293. View

13.

Sung K, Lee S, Yoo K, Jung H, Cho E, Koo H . Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant. 2007; 40(1):37-45. DOI: 10.1038/sj.bmt.1705691. View

14.

Canete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C . Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol. 2009; 27(7):1014-9. DOI: 10.1200/JCO.2007.14.5839. View

15.

Kushner B, Kramer K, Modak S, Qin L, Cheung N . Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer. 2010; 116(12):3054-60. DOI: 10.1002/cncr.25232. View

16.

Santana V, Furman W, McGregor L, Billups C . Disease control intervals in high-risk neuroblastoma. Cancer. 2008; 112(12):2796-801. DOI: 10.1002/cncr.23507. View

17.

Kushner B, Wolden S, LaQuaglia M, Kramer K, Verbel D, Heller G . Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol. 2001; 19(11):2821-8. DOI: 10.1200/JCO.2001.19.11.2821. View

18.

Conte M, Parodi S, De Bernardi B, Milanaccio C, Mazzocco K, Angelini P . Neuroblastoma in adolescents: the Italian experience. Cancer. 2006; 106(6):1409-17. DOI: 10.1002/cncr.21751. View

19.

Kushner B, Kramer K, Modak S, Cheung N . High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan. Pediatr Blood Cancer. 2010; 56(3):403-8. DOI: 10.1002/pbc.22855. View

20.

Pearson A, Pinkerton C, Lewis I, Imeson J, Ellershaw C, Machin D . High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008; 9(3):247-56. DOI: 10.1016/S1470-2045(08)70069-X. View